Citius Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on September 15, 2016, by Citius Pharmaceuticals, Inc. (Citius), a Nevada corporation. The report details the termination of material definitive agreements regarding the company's weight loss product, Suprenza, and the results of the 2016 Annual Meeting of Shareholders held on September 15, 2016.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. However, it notes that Citius has not previously received royalties from Suprenza and that the withdrawal of the New Drug Application from the FDA eliminates ongoing regulatory expenses associated with annual FDA fees.
Material Changes
- Termination of Agreements: On September 21, 2016, Citius terminated agreements with Prenzamax LLC, Akrimax Pharmaceuticals LLC, and Alpex Pharma S.A. regarding the exclusive license, supply, and commercialization of Suprenza. Shipments and marketing obligations ceased effective June 30, 2016.
- Capital Structure: The company amended its Articles of Incorporation to increase authorized common stock from 90,000,000 to 200,000,000 shares.
- Corporate Governance: Shareholders approved a potential reverse stock split (ratio between 1-for-8 and 1-for-20) and a change of state of incorporation from Nevada to Delaware.
Outlook, Risks, and Management Commentary
Management commentary indicates a strategic shift away from the Suprenza partnership, with no further payment obligations under the terminated agreements except for accrued amounts prior to June 30, 2016. The filing highlights a related party transaction, noting that Leonard Mazur, the Executive Chairman of Citius, is also the co-founder and Vice Chairman of Akrimax. Risks include the execution of the authorized reverse stock split and the logistical complexities of the proposed reincorporation in Delaware.
Investor Verification Checklist
- Confirm the effective date and financial impact of the terminated agreements with Prenzamax and Akrimax.
- Verify the status of the New Drug Application withdrawal and the cessation of FDA annual fees.
- Monitor the Board's decision on the specific ratio for the authorized reverse stock split.
- Review the timeline and regulatory requirements for the reincorporation from Nevada to Delaware.
- Assess the implications of the related party relationship between Citius leadership and Akrimax.